Lv11
35 积分 2021-01-21 加入
Radiotheranostics in oncology: current challenges and emerging opportunities
5小时前
待确认
Radiotheranostic landscape: A review of clinical and preclinical development
5小时前
已完结
Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors
1个月前
已关闭
Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma
3个月前
已完结
Breast cancer
5个月前
已完结
Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
5个月前
已关闭
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
5个月前
已完结
Exploiting the folate receptor α in oncology
5个月前
已完结
Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma
7个月前
已完结
皖公网安备34019202002308
